Yttrium-90-EDTMP

A radiotherapeutic agent in the treatment of leukaemias

A. A. Keeling, Andrew T M Vaughan, R. P. Beaney

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be reduced by 50% using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity.

Original languageEnglish (US)
Pages (from-to)74-78
Number of pages5
JournalBritish Journal of Cancer
Volume60
Issue number1
StatePublished - 1989
Externally publishedYes

Fingerprint

Leukemia
Chelation Therapy
Yttrium
Bone and Bones
Pentetic Acid
Citric Acid
Half-Life
Acetates
Salts
Radiation
Calcium
Morbidity
Therapeutics
yttrium ethylenediaminetetra(methylenephosphonic acid)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yttrium-90-EDTMP : A radiotherapeutic agent in the treatment of leukaemias. / Keeling, A. A.; Vaughan, Andrew T M; Beaney, R. P.

In: British Journal of Cancer, Vol. 60, No. 1, 1989, p. 74-78.

Research output: Contribution to journalArticle

@article{c44ad28553f44475a4b86cf4420eb0e3,
title = "Yttrium-90-EDTMP: A radiotherapeutic agent in the treatment of leukaemias",
abstract = "Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be reduced by 50{\%} using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity.",
author = "Keeling, {A. A.} and Vaughan, {Andrew T M} and Beaney, {R. P.}",
year = "1989",
language = "English (US)",
volume = "60",
pages = "74--78",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Yttrium-90-EDTMP

T2 - A radiotherapeutic agent in the treatment of leukaemias

AU - Keeling, A. A.

AU - Vaughan, Andrew T M

AU - Beaney, R. P.

PY - 1989

Y1 - 1989

N2 - Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be reduced by 50% using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity.

AB - Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be reduced by 50% using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity.

UR - http://www.scopus.com/inward/record.url?scp=0024313271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024313271&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 74

EP - 78

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -